Business
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA approvalTwo patients in the ongoing phase 2 trial have now exceeded 17 months on stenoparib treatment Boston (February 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PAR
About this update from Allarity Therapeutics, Inc.
[{"type":"image","alt":"Allarity Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allarity Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H2n2B7OUZZNZTe8771hvug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already delivered","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA approval","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Two patients in the ongoing phase 2 trial have now exceeded 17 months on stenoparib treatment ","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":290,"olType":false},{"type":"text","content":"Boston (February 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the new protocol for its Phase 2 clinical trial of stenoparib in ovarian cancer is set to begin and will be expected to provide critical data by end of summer 2026 for a pivotal registration trial.","length":587,"tagName":"p"},{"type":"text","content":"The new protocol design was constructed following in-depth review of the Company’s ongoing Phase 2 clinical data in collaboration with key ovarian cancer thought leaders and treating physicians, including the gynecologic oncologists who have been treating patients with stenoparib in the ongoing phase 2 study. This comprehensive review revealed compelling evidence for stenoparib’s durable clinical benefit in platinum-resistant, advanced ovarian cancer patients, including a complete, confirmed response as well as two patients remaining on therapy ...